Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Recruiting

Phase 2

TalquetamabSubcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Sponsor:

Larysa Sanchez

Code:

NCT06827860

Conditions

Multiple Myeloma in Relapse

Eligibility Criteria

Sex: All

Age: 70+

Healthy Volunteers: Not accepted

Interventions

Talquetamab

Daratumumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Larysa Sanchez on 2025-04-09.